Biophysical models as an approach to study passive absorption in drug development: 6-fluoroquinolones
- PMID: 7562422
- DOI: 10.1002/jps.2600840622
Biophysical models as an approach to study passive absorption in drug development: 6-fluoroquinolones
Abstract
A preliminary study attempting to assess and explain the intestinal absorption of a series of antibacterial 7-piperazinyl-6-fluoroquinolones is presented. The synthesis, n-octanol partition coefficients, intrinsic rat gut in situ absorption rate constants, and in vitro antibacterial activity data found for these homologous compounds are described. A fluorimetric, reverse-phase HPLC method was performed for the quantification of the quinolones in absorption and partition samples. Equations based on two classic biophysical absorption models are given for predicting the intrinsic absorption features of the series according to the partition data or merely single structural parameters. In situ absorption rate constants were found to increase by a factor of 9.7-13.5 for moderately lipophilic derivatives relative to the simplest compound, while antibacterial activity decreased only by a factor of 4. In vivo absorption tests with two representative members of the series were carried out and the results showed a good accordance with those found in situ. This makes these compounds or related ones with similar partition features excellent candidates for further pharmacokinetic and pharmacological testing. The study can serve as an example of how to prevent potential absorption problems associated with the development of new drugs.
Similar articles
-
Validation of a biophysical drug absorption model by the PATQSAR system.J Pharm Sci. 1999 Apr;88(4):398-405. doi: 10.1021/js980370+. J Pharm Sci. 1999. PMID: 10187749
-
Intrinsic absolute bioavailability prediction in rats based on in situ absorption rate constants and/or in vitro partition coefficients: 6-fluoroquinolones.J Pharm Sci. 2000 Nov;89(11):1395-403. doi: 10.1002/1520-6017(200011)89:11<1395::aid-jps3>3.0.co;2-u. J Pharm Sci. 2000. PMID: 11015685
-
A novel approach to determining physicochemical and absorption properties of 6-fluoroquinolone derivatives: experimental assessment.Eur J Pharm Biopharm. 2002 May;53(3):317-25. doi: 10.1016/s0939-6411(02)00013-9. Eur J Pharm Biopharm. 2002. PMID: 11976020
-
Lomefloxacin clinical pharmacokinetics.Clin Pharmacokinet. 1993 Jul;25(1):6-19. doi: 10.2165/00003088-199325010-00002. Clin Pharmacokinet. 1993. PMID: 8394795 Review.
-
Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.Clin Infect Dis. 1996 Dec;23 Suppl 1:S19-24. doi: 10.1093/clinids/23.supplement_1.s19. Clin Infect Dis. 1996. PMID: 8953102 Review.
Cited by
-
Computational approaches for modeling human intestinal absorption and permeability.J Mol Model. 2006 Jul;12(5):577-89. doi: 10.1007/s00894-005-0065-z. Epub 2006 Apr 1. J Mol Model. 2006. PMID: 16583199 Free PMC article.
-
Modeling kinetics of subcellular disposition of chemicals.Chem Rev. 2009 May;109(5):1793-899. doi: 10.1021/cr030440j. Chem Rev. 2009. PMID: 19265398 Free PMC article. Review. No abstract available.
-
Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice.Mol Pharm. 2012 Sep 4;9(9):2442-9. doi: 10.1021/mp200647a. Epub 2012 Aug 3. Mol Pharm. 2012. PMID: 22812541 Free PMC article.
-
Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures.Eur J Drug Metab Pharmacokinet. 2016 Dec;41(6):795-806. doi: 10.1007/s13318-015-0310-5. Eur J Drug Metab Pharmacokinet. 2016. PMID: 26602766
-
Interethnic differences in pharmacokinetics of antibacterials.Clin Pharmacokinet. 2015 Mar;54(3):243-60. doi: 10.1007/s40262-014-0209-3. Clin Pharmacokinet. 2015. PMID: 25385446
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources